MedTrace Logo

Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function

NCT06496217 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-10-28

No results posted yet for this study

Summary

Evaluate the Safety and Pharmacokinetics of MBX 2109 in Adult Subjects with Normal and Impaired Renal Function

Conditions

  • Renal Impairment

Interventions

DRUG

MBX 2109

Group 2: Subjects with moderate renal impairment (eGFR ≥ 30 and \< 60 mL/min)

DRUG

MBX 2109

Group 3: Subjects with severe renal impairment (eGFR \< 30 mL/min), or kidney failure and not receiving dialysis

DRUG

MBX 2109

Group 4: Matched healthy subjects with normal renal function (eGFR ≥ 90 mL/min)

DRUG

MBX 2109

Group 1: Subjects with mild renal impairment (eGFR ≥ 60 and \< 90 mL/min)

Sponsors & Collaborators

  • MBX Biosciences

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-13
Primary Completion
2025-09-04
Completion
2025-09-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06496217 on ClinicalTrials.gov